

Video EEG

Adjudication Guideline

Rule Category:
Billing

Ref: No:
2017-BR-0025

Version Control:
Version No.2.0

Effective Date:
29/12/2017

Revision Date:
29/12/2024

Approved by:
Daman

Responsible:
Medical Standards
& Research

**Related Adjudication
Guidelines:**
N/A

Table of Contents

1.	Abstract	3
1.1	For Members	3
1.2	For Medical Professionals	3
2.	Scope	3
3.	Adjudication Policy	4
3.1	Eligibility / Coverage Criteria	4
3.2	Requirements for Coverage	4
3.3	Non-Coverage.....	4
3.4	Payment and Coding Rules.....	4
4.	Denial Codes	5
5.	Appendices	5
5.1	References	5
5.2	Revision History	5

1. Abstract

1.1 For Members

Video EEG (electroencephalograph) records what you are doing or experiencing on video while an EEG test records the electrical activity of the brain or brainwaves.

The purpose is to be able to see what happens when you have a seizure or an event that is suspected to be a seizure. The video is compared to what the EEG records at the same time. Sounds that occur during the testing are also recorded to pick up if a person talks or makes sounds during an event.

By doing this, doctors reading the EEG can tell if the event is related to abnormal electrical activity in the brain. If so, then doctors would call this a seizure related to epilepsy.

1.2 For Medical Professionals

Video-electroencephalographic (EEG) monitoring is an important neurodiagnostic technique that is used to record the electrical brain activity and behavioral activity such as involuntary episodes of movements /consciousness.

During testing, seizures may be provoked by the following methods:

- Hyperventilation
- Photic stimulation
- Sleep deprivation
- Withdrawal of drug
- Exercise or other less common triggers may provoke seizures

2. Scope

The scope of this adjudication rule highlights the coverage of Video EEG for health insurance plans administered by Daman subject to policy terms and conditions.

3. Adjudication Policy

3.1 Eligibility / Coverage Criteria

The eligibility criteria for Video EEG monitoring in adults:

- Patient has sign and symptoms and alternative evaluation including ambulatory EEG is inconclusive or it cannot be used because:
 - Withdrawal of drug seems unsafe as out-patient
 - Seizures/similar events occur infrequently (i.e. fewer than 3 times per week)
 - Intractable recurrent seizures persist
- Localization of seizures for patient being considered for epilepsy surgery
- Need to determine diagnosis, nature, frequency of seizures in patients with poor ability to communicate:
 - Indistinct seizure event
 - Tampered ability to communicate
 - Encephalopathy (altered mental status)

The eligibility criteria Video EEG monitoring in child:

All of above, in addition to traumatic brain injury with subclinical post-traumatic seizures.

Once the cause of seizures and specific type of epilepsy has been established, continued video EEG monitoring is not medically necessary. In such cases, response to therapy can be assessed using standard EEG monitoring or ambulatory EEG monitoring.

3.2 Requirements for Coverage

- ICD and CPT codes must be coded to the highest level of specificity.
- Failure to submit, upon request or when requesting a clinical history, indication the need for testing will result in rejection of claim.

3.3 Non-Coverage

Not covered for visitor plan.

3.4 Payment and Coding Rules

Please apply Regulator payment rules and regulations and relevant coding manuals for ICD, CPT.

4. Denial Codes

Code	Code Description
MNEC-003	Service is not clinically indicated based on good clinical practice
MNEC-004	Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities
MNEC-005	Service /supply may be appropriate, but too frequent
NCOV-003	Service(s) is (are) not covered
PRC-002	Payment is included in allowance for another service

5. Appendices

5.1 References

- <https://www.uptodate.com/contents/video-and-ambulatory-eeg-monitoring-in-the-diagnosis-of-seizures-and-epilepsy>
- <https://www.epilepsy.com/diagnosis/eeg/video-eeg>
- <https://www.sciencedirect.com/science/article/abs/pii/B9780444640321000114>
- <https://pubmed.ncbi.nlm.nih.gov/31277846/>

5.2 Revision History

Date	Change(s)
29/12/2017	Release V1.0
29/12/2024	Release V2.0 <ul style="list-style-type: none"> • New Template • General content update • References updated

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by The National Insurance Company – Daman (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.